Medimmune Ventures, Inc. Sells 200,000 Shares of G1 THERAPEUTICS (GTHX) Stock
G1 THERAPEUTICS (NASDAQ:GTHX) major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $20.01, for a total transaction of $4,002,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
G1 THERAPEUTICS (GTHX) traded up $0.28 during trading on Wednesday, hitting $20.25. 81,200 shares of the stock traded hands, compared to its average volume of 95,766. G1 THERAPEUTICS has a 52 week low of $12.04 and a 52 week high of $28.67.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System acquired a new stake in G1 THERAPEUTICS during the 3rd quarter valued at $319,000. Schwab Charles Investment Management Inc. acquired a new position in G1 THERAPEUTICS during the 3rd quarter worth $364,000. American International Group Inc. acquired a new position in G1 THERAPEUTICS during the 3rd quarter worth $130,000. Chartwell Investment Partners LLC lifted its position in shares of G1 THERAPEUTICS by 5.0% in the 3rd quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock worth $2,303,000 after buying an additional 4,388 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in G1 THERAPEUTICS in the 3rd quarter valued at about $568,000. 40.23% of the stock is owned by institutional investors and hedge funds.
About G1 THERAPEUTICS
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.